Sign in

    Jacob Putman

    Vice President and Equity Research Analyst at Barclays

    Jacob Putman is a Vice President and Equity Research Analyst at Barclays, specializing in the coverage of the healthcare and pharmaceuticals sectors. He provides research and investment analysis on major publicly traded companies, delivering actionable insights to institutional clients and buy-side investors, although specific company names and detailed performance metrics are currently not publicly documented. Putman began his career as an analyst at Barclays and has developed expertise in sector-specific financial modeling and market strategy, with no prior experience at other major investment firms identified. He holds relevant securities licenses, is FINRA registered, and is noted within the industry for his analytical rigor and sector specialization.

    Jacob Putman's questions to Fortrea Holdings (FTRE) leadership

    Jacob Putman's questions to Fortrea Holdings (FTRE) leadership • Q2 2025

    Question

    Jacob Putman, on behalf of Luke Surgatt at Barclays, asked if the 2026 framework for backlog and sales mix remains intact following the quarter's bookings, and what actions are being taken to build confidence with 'new to Fortrea' customers.

    Answer

    CFO Jill McConnell affirmed that the framework holds, noting that post-spin awards now constitute about 30% of full-service clinical development revenue and are on track to exceed 50% in the second half of 2026. CEO Anshul Thakral added that resolving the CEO transition uncertainty is critical, and his immediate priority is to actively engage with both current and prospective customers to rebuild confidence.

    Ask Fintool Equity Research AI